title: Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Pachner
authors.forename: Jennifer
authors.initials: J
authors.lastname: Brady
authors.forename: Israel
authors.initials: I
authors.lastname: Steiner
authors.forename: Kavitha
authors.initials: K
authors.lastname: Narayan
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000906:Antibodies / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D009500:Neutralization Tests; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000906:Antibodies; D016899:Interferon-beta; D008775:Methylprednisolone